Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are:
Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain.
Participants will be asked to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enhanced Recovery Protocol | Experimental | This group will receive the following: 50g carbohydrate drink 2 hours prior to surgery 300mg of gabapentin 30 minutes prior to surgery 650mg of acetaminophen 30 minutes prior to surgery 0.25% bupivicaine local anesthetic intraoperatively assisted ambulation 12 hours after surgery |
|
| Control group | No Intervention | This group is a retrospective review of 30 patients who have undergone a live donor kidney transplant during 1/1/2022-12/31/2024 will be selected and undergo a retrospective chart review for the same data collection points. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pre-operative carbohydrate drink | Dietary Supplement | 50 g of carbohydrate drink 2 hours before surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Numerical Rating Scale (NRS) (0-10) | Patient reported pain on a scale from 0 (no pain) to 10 (the worst possible pain) | From enrollment to the end of treatment at 30 days |
| Narcotic Use | milligram morphine equivalents (MME) | From enrollment to the end of treatment at 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events | unfavorable medical occurence | From enrollment to the end of treatment at 30 days |
| Hospital readmission | readmission to any hospital within 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard Ruiz, MD | Baylor Scott & White All Saints Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baylor Scott & White All Saints Medical Center | Fort Worth | Texas | 76104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| D000077206 | Gabapentin |
| D002045 | Bupivacaine |
| D016138 | Walking |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Acetaminophen | Drug | 650mg acetaminophen 30 minutes prior to surgery |
|
|
| Gabapentin | Drug | 300 mg gabapentin 30 minutes prior to surgery |
|
|
| Bupivacaine | Drug | intraoperative local anesthetic |
|
|
| Ambulation | Other | Assisted ambulation 12 hours after surgery |
|
| From enrollment to the end of treatment at 30 days |
| Length of Stay | total hospital length of stay | From enrollment to the end of treatment at 30 days |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| Aniline Compounds |
| D000588 | Amines |
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D008124 | Locomotion |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
| D015444 | Exercise |
| D009043 | Motor Activity |